Represcription of Low-Dose Acetylsalicylic Acid After Discontinuation in Patients Receiving Treatment for Secondary Cardiovascular Disease Prevention in the UK
In conclusion, approximately 85 % of patients who discontinued low-dose ASA therapy were subsequently represcribed ASA during the study period. Comorbidities and comedication use affected represcription rates.
Source: American Journal of Cardiovascular Drugs - Category: Cardiology Source Type: research
More News: Atrial Fibrillation | Cardiology | Cardiovascular | Coumadin | Databases & Libraries | Depression | Diabetes | Diabetes Mellitus | Drugs & Pharmacology | Eating Disorders & Weight Management | Endocrinology | Gastroenterology | Heart | Obesity | Primary Care | Study | Warfarin